{"nctId":"NCT00645099","briefTitle":"A 6 Month Study to Compare the Metabolic Effects of Paliperidone ER and Olanzapine in Patients With Schizophrenia","startDateStruct":{"date":"2007-10"},"conditions":["Schizophrenia"],"count":462,"armGroups":[{"label":"001","type":"EXPERIMENTAL","interventionNames":["Drug: paliperidone ER"]},{"label":"002","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: olanzapine"]}],"interventions":[{"name":"olanzapine","otherNames":[]},{"name":"paliperidone ER","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient meets the DSM-IV criteria for schizophrenia\n* Patient has a PANSS total score at screening of 60 to 100, inclusive\n* Patient must, in the opinion of the investigator, benefit from treatment with paliperidone ER or olanzapine\n* Patients on lipid-lowering therapy must be on a stable dose for at least 4 weeks for statins, niacin, ezetimibe and resins or for at least 12 weeks for fibrates\n* Female patients must be postmenopausal (for at least 1 year), surgically sterile, abstinent, or, if sexually active, be practicing and effective method of birth control (e.g. prescription oral contraceptives, contraceptive injections, intrauterine device, double-barrier method, contraceptive patch, male partner sterilization) before entry and throughout the study\n* Women of child-bearing potential must have a negative urine pregnancy test at screening\n* Patient is healthy on the basis of a physical examination and vital signs at screening\n\nExclusion Criteria:\n\n* Patient has previously been treated with paliperidone ER, olanzapine, or clozapine within the past 6 months or has never been treated with an antipsychotic before\n* Treatment with a depot antipsychotic within the past 3 months\n* Treatment with a mood stabilizer or a recently initiated antidepressant (\\<= 3 months)\n* Patient has abnormal fasting plasma glucose (\\> 126 mg/dL) or fasting triglycerides (TG) levels (\\> 400 mg/dL) at screening\n* Relevant history of any significant and/or unstable cardiovascular, respiratory, neurologic (including seizures or significant cerebrovascular), renal, hepatic, endocrine, or immunologic diseases, including recent or present clinically relevant laboratory abnormalities (as deemed by the investigator)\n* History or current symptoms of tardive dyskinesia\n* History of neuroleptic malignant syndrome\n* Pregnant or breast-feeding female","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline to End Point in the Triglycerides (TG) to High Density Lipoprotein (HDL) Ratio (TG:HDL Ratio)","description":"Plasma fasting TG and HDL concentrations were measured to determine the TG:HDL ratio.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.08","spread":"1.10"},{"groupId":"OG001","value":"0.42","spread":"1.19"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to End Point in Triglycerides","description":"The TG level was assessed under fasted conditions.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.01","spread":"0.77"},{"groupId":"OG001","value":"0.36","spread":"0.96"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to End Point in High Density Lipoprotein","description":"The HDL level was assessed under fasted conditions.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.25"},{"groupId":"OG001","value":"-0.04","spread":"0.24"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to End Point in Total Cholesterol","description":"The total cholesterol level was assessed under fasted conditions.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0263","spread":"0.7841"},{"groupId":"OG001","value":"0.2886","spread":"0.8493"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to End Point in Low Density Lipoprotein Cholesterol (Friedwald QT)","description":"The level of low density lipoprotein cholesterol was calculated using the Friedwald QT formula.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0029","spread":"0.6726"},{"groupId":"OG001","value":"0.1892","spread":"0.7361"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to End Point in Converted Insulin","description":"The insulin level was assessed under fasted conditions.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7397","spread":"89.9776"},{"groupId":"OG001","value":"17.2327","spread":"84.6255"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to End Point in Fasting Glucose","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2071","spread":"0.4953"},{"groupId":"OG001","value":"0.0769","spread":"0.4781"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to End Point in Homeostatic Model Assessment of Beta-cell Function (HOMA-%B)","description":"HOMA-%B is used to assess beta-cell function. HOMA-%B is a dimensionless measure of beta-cell function (higher values present increased insulin secretion for a given glucose level).\n\nHOMA-%B is normalized so that lean, healthy individuals will have values of HOMA-%B close to 100%.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.54","spread":"85.91"},{"groupId":"OG001","value":"18.82","spread":"147.63"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to End Point in Homeastatic Model Assessment of Insulin Resistance (HOMA-IR)","description":"HOMA-IR is used to assess insulin resistance (IR). HOMA-IR is a dimensionless measure of insulin resistance (higher values present more insulin resistance. HOMA-IR are normalized so that lean, healthy individuals will have values of HOMA-IR close to 1.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.28","spread":"5.39"},{"groupId":"OG001","value":"0.43","spread":"5.37"}]}]}]},{"type":"SECONDARY","title":"Number of Patients Meeting the Criteria for Type 2 Diabetes Mellitus During Follow-up","description":"Fasting plasma glucose ≥126 mg/dL or 2-hour post-load plasma glucose ≥200 mg/dL during an oral glucose tolerance test (OGTT) or initiated use of glucose-lowering agents during the course of the study.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Onset of Impaired Glucose Tolerance","description":"Glucose ≥140 mg/dL, \\<200 mg/dL after a 75g OGTT.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Impaired Fasting Glucose","description":"Post-baseline glucose level under fasted conditions ≥100 mg/dL but \\<126 mg/dL.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null},{"groupId":"OG001","value":"66","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline at End Point of the Insulinogenic Index","description":"The insulinogenic index, defined as (insulin at 30 min - insulin at 0)/(glucose at 30 min \\[G(30)\\] - glucose at 0 \\[G(0)\\]) was used as a measure of early insulin secretion in response to the OGTT. Because the index is undefined when G(30)-G(0)=0, and poorly defined when G(30)-G(0)\\<0, the index was only calculated when G(30)\\>G(0).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.21","spread":"173.46"},{"groupId":"OG001","value":"33.78","spread":"259.56"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline at End Point of Mari-Type Analysis of Glucose Sensitivity for Insulin","description":"As another measure of beta-cell function, the relationship between plasma insulin and glucose concentrations during the OGTT was calculated using a simplified version of the method described by Mari et al. (Mari A, Sallas WM, He YL, Watson C, Ligueros-Saylan M, Dunning BE, Deacon CF, Holst JJ, Foley JE. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab. 2005; 90:4888-4894.).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.63","spread":"79.53"},{"groupId":"OG001","value":"17.28","spread":"94.51"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline at End Point in Body Weight","description":"Patients were weighed lightly clothed. The same amount of clothing had to be worn each time.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.16","spread":"4.57"},{"groupId":"OG001","value":"3.81","spread":"5.87"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline at End Point in Body Mass Index (BMI)","description":"BMI is calculated by dividing the body weight (in kg) by the square of height (in meters).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.43","spread":"1.59"},{"groupId":"OG001","value":"1.32","spread":"1.99"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline at End Point in Waist Circumference","description":"Patients had to be instructed to stand erect with abdomen relaxed, arms at sides, feet together, and weight divided equally over both legs. The tape measure was placed around the bare abdomen midway between the palpated iliac crest and the palpated lowest rib margin in the left and right mid-axillary lines. A nonstretchable tape was evenly placed around the natural waist covering the left and right natural-waist marks. The measurement scale had to face outward, and there could not be any twists in the tape. The tape had to be just touching the skin but not compressing the soft tissue.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.70","spread":"5.39"},{"groupId":"OG001","value":"3.38","spread":"6.18"}]}]}]},{"type":"SECONDARY","title":"Number of Patients First Meeting the NCEP/ATP III Criteria for Metabolic Syndrome During Follow-up","description":"Metabolic syndrome is defined according the Third Report of the National Cholesterol Education Program Expert Panel on\n\nDetection, Evaluation, and Treatment of High Blood Cholesterol in Adults (NCEP/ATPIII) of which 3 out of 5 criteria must be met:\n\n* waist circumference men \\> 102 cm; waist circumference women \\> 88 cm\n* TG ≥ 150 mg/dL\n* HDL cholesterol men \\<40 mg/dL; HDL cholesterol women \\<50 mg/dL\n* Blood pressure systolic ≥ 130 mmHg; Blood pressure diastolic ≥ 85 mmHg\n* Fasting glucose ≥ 110 mg /dL","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"38","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to End Point in Total Positive and Negative Syndrome Scale Score (PANSS)","description":"PANSS is an investigator-rated 30-item scale to assess the neuropsychiatric symptoms of schizophrenia. The PANSS provided a total score and scores for 3 subscales, the positive subscale (7 items), the negative subscale (7 items), and the general psychopathology subscale (16 items), each rated on a scale of 1 (absent) to 7 (extreme).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.50","spread":"15.86"},{"groupId":"OG001","value":"-16.60","spread":"15.02"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":21,"n":239},"commonTop":["Weight increased","Somnolence","Insomnia","Headache","Anxiety"]}}}